Fundraising Fox

Hopewell Therapeutics

Woburn, US · Founded 2018 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

QX
Qiaobing XuNamed on SEC filing

Board

NS
Nan ShenBoard director
TV
Thomas V. Hennessey, IIIBoard director
XJ
Xutian JingBoard director
XF
Xiaowen FemgBoard director
CT
C. Thomas PaschallBoard director

Investors · 1

Hike CapitalreportedBeijing

Reported raises · per SEC filings

Form D private placements

$25.9M disclosed across 5 rounds · 2020–2025

▶$2.5MraisedSep 2025 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nan ShenDirector
  • Qiaobing XuExecutive Officer, Director
  • Thomas V. Hennessey, IIIDirector
  • Xutian JingDirector
  • Xiaowen FemgDirector
  • C. Thomas PaschallDirector
Offering amount
$3.5M
Amount sold
$2.5M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.8MraisedMay 2024 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas HennesseyDirector
  • Nan ShenDirector
  • Qiaobing XuExecutive Officer, Director
  • Jake XiaDirector
  • Xutian JingDirector
Offering amount
$10M
Amount sold
$7.8M
First sale
May 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.1MraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • XUTIAN JINGDirector
  • THOMAS V HENNESSEYDirector
  • JAKE XIADirector
  • QIAOBING XUExecutive Officer, Director
  • HOWARD ROSENDirector
Offering amount
$7.1M
Amount sold
$7.1M
First sale
Jan 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8MraisedOct 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas V. HennesseyDirector
  • Qiaobing XuExecutive Officer, Director
Offering amount
$8M
Amount sold
$8M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Qiaobing XuExecutive Officer, Director
Offering amount
$500K
Amount sold
$500K
First sale
Dec 2020
Incorporated
Corporation, Massachusetts, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Hopewell Therapeutics Inc. - MassBiomassbio.org · Sep 2025Hopewell Therapeutics: $25 Million To Develop Next Generation Of Tissue-Targeted Lipid Nanoparticlespulse2.com · Jun 2023Hopewell Therapeutics raises funds for genomic medicinespharmaceutical-technology.com · Jun 2023Hopewell Gets up to $25 Million in Seed Financing to Advance Next Gen LNPs - Global Genesglobalgenes.org · Jun 2023Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid Nanoparticles for Targeted Delivery of Genomic Medicinesprnewswire.com · Jun 2023Hopewell Therapeutics Raises $25M in Seed Financingfinsmes.com · Jun 2023

Frequently asked questions

Who are Hopewell Therapeutics's investors?
Hopewell Therapeutics's investors include Hike Capital.
How much funding has Hopewell Therapeutics raised?
Hopewell Therapeutics has disclosed $25.9M raised across 5 rounds.
Where is Hopewell Therapeutics headquartered?
Hopewell Therapeutics is headquartered in Woburn, US.